Aim: To compare efficacy of different formulations of TRT in treatment of hypogonadism
Background: Different formulations of testosterone are available for treatment of hypogonadism in men. TRT improves libido, sexual function, bone density and general well-being. We analysed data of 106 patients on TRT to compare efficacy of topical and injectable formulations.
Methods: Its a retrospective data analysis of 106 patient receiving TRT between 2009 and 2019. Data was collected from electronic outpatient clinic letters and blood results. It included type of TRT, patient satisfaction in terms of libido, erectile function and general well-being, testosterone levels achieved, patients in whom preparation was changed due to any reason, and in whom PDE5 inhibitors (PDE5I) were added to therapy.Results with different formulations were compared.
Results: Out of 106 patients, 38 received testogel, 35 tostran, 4 testim gel, 40 nebido and 10 sustanon injections. All patients on testim (100%), 9 on sustanon (90%), 28 on tostran (80%), 29 on testogel (76%) and 27 on nebido (68%) reported good effects and satisfaction with therapy. Analysis of testosterone levels showed a mean value (in nmol/l) of 14.6 with testogel, 11.5 with tostran and 9.3, 18.3 and 8.5 with testim, sustanon and nebido respectively. 21 patients were switched from one preparation to other. Out of 21, 6 patients needed a change due to side effects, 4 had poor response, 3 patients each due to low testosterone levels and non-availability of preparation and no data was available for 5 patients. In 22 patients PDE5I were added to TRT,10 out of these were on nebido followed by testogel (7) and tostran (5).
Conclusion: Majority of our patients achieved symptomatic benefits, regardless of type of the preparation they were using, with most successful being testim gel (but only 4 were on testim). Good serum levels were achieved along with 90% satisfaction with sustanon.